This is the authors' abstract. We don't add key points for this paper.
Research leading to characterization, quantification, and functional attribution of the microbes throughout the human body has led to many drug-development programs. These programs aim to manipulate a patient's microbiome through the addition of new strains or functions, the subtraction of deleterious microbes, or the rebalancing of the existing population through various drug modalities. Here, we present a general overview of those modalities with a specific focus on bacterial live biotherapeutic products (LBPs). The bacterial LBP modality has unique concerns to ensure product quality, thus, topics related to manufacturing, quality control, and regulation are addressed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
McChalicher et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: